Lanreotide is an octapeptide analogue of natural somatostatin.
It is indicated for the treatment of acromegaly when the circulating levels of growth hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy. 

It is also indicated for the treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy.
It is also indicated for the relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours.
Under Development
Active ingredient Pharmaceutical form Package Therapeutic target
  • Lanreotide LAI
  • Long-Acting Injectable
  • 60mg/vial
  • 90mg/vial
  • 120mg/vial
  • Treatment of acromegaly, thyrotropic adenomas and neuroendocrine tumours

Other products in "International"